首页> Expert review of hematology> What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?

What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?

导出原文传递

翻译打印收藏纠错

第一作者： Harrington, Patrick

作者： Harrington, Patrick ^[1] ; Radia, Deepti ^[2] ; de Lavallade, Hugues

作者单位： Guys & St Thomas NHS Fdn Trust, Dept Haematol, London SE1 9RT, England ^[1] Kings Coll London Sch Med, Dept Haematol Med, London, England ^[2]

关键词 Chronic myeloid leukemia TKI discontinuation treatment-free remission immune surveillance

发布时间 2020-10-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Expert review of hematology

2020年13卷1/6期

213-222页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Expert review of hematology

2020年13卷1/6期

213-222页

检索历史清除

What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?

Expert review of hematology

相似文献

同项目论文

Expert review of hematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?

Expert review of hematology

相似文献

同项目论文

Expert review of hematology

相关期刊

检索历史清除